Tue.Jul 23, 2024

article thumbnail

July 23, 2024: Article From Ethics and Regulatory Core Highlights Key Challenges for Pragmatic Trials

Rethinking Clinical Trials

In an invited commentary published this month in Circulation: Cardiovascular Quality and Outcomes , authors from the NIH Pragmatic Trials Collaboratory’s Ethics and Regulatory Core describe the recurring and emerging ethical issues in pragmatic clinical trials. Coauthors Caleigh Propes, Stephanie Morain, and Pearl O’Rourke discuss 3 key challenges facing pragmatic trials researchers: waivers and alterations of informed consent and their implications for transparency managing and resp

Trials 317
article thumbnail

Johnson & Johnson submits sNDA for SPRAVATO to treat depression

Pharmaceutical Technology

Johnson & Johnson is seeking approval for SPRAVATO for treatment-resistant depression with the submission of an sNDA to the US FDA.

254
254
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Eyelash Extensions Can Be Seriously Dangerous, Expert Warns

AuroBlog - Aurous Healthcare Clinical Trials blog

Ultra long, thick eyelashes might be in vogue but are they worth the expense – and the risk to health? Our natural eyelashes perform important functions. The eye is exposed to the elements so it’s a window for bacteria and viruses to enter the body – potentially causing death.

Bacteria 245
article thumbnail

Startup led by former J&J executives raises $165M for cancer, immune disease drugs

Bio Pharma Dive

Peter Lebowitz, who for years led J&J’s oncology R&D, is the CEO of the startup, called Third Arc Bio and launched by Omega Funds in 2022.

Drugs 221
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Doctors at Sahyadri Hospitals Pune warn of rising pulmonary embolism cases linked to international travel

AuroBlog - Aurous Healthcare Clinical Trials blog

Over the last two years, Sahyadri Hospitals in Pune has observed a troubling trend of increase in cases of pulmonary embolism (PE) associated with long-haul international travel. This insight comes after the successful treatment of 17 PE cases through mechanical thrombectomy at the hospital—a procedure chosen for its efficacy when traditional clot-dissolving medications are unsuitable.

Doctor 185
article thumbnail

Merck claims late-stage study success for RSV antibody

Bio Pharma Dive

The drug, a rival to Sanofi and AstraZeneca’s fast-selling Beyfortus, met its main goals in a Phase 3 trial. But undisclosed study results leave its full potential unclear.

Antibody 173

More Trending

article thumbnail

Study reveals two proteins that may contribute to stroke recurrence or other MACEs

Pharma Times

The life-threatening medical condition affects 100,000 people in the UK every year

Protein 125
article thumbnail

J&J drops Addex’s epilepsy treatment after flunking in Phase II

Pharmaceutical Technology

A Phase II trial with Johnson and Johnson (J&J) and Addex’s epilepsy drug had failed to meet the primary endpoint in April.

Trials 147
article thumbnail

Amid Wegovy and Ozempic boom, Novo eyes new facility with 200-acre land buy in Denmark

Fierce Pharma

After making major manufacturing outlays in places like China and the United States earlier this year, Novo Nordisk is returning to its Danish roots. | Earlier this month, Novo Nordisk purchased a 200-acre site in Odense, Denmark’s third largest city, the company has confirmed. Novo is now set to kick off preparatory excavation work for a potential new production plant.

article thumbnail

HHS gives thumbs down to bluebird’s fertility support programme

Pharmaceutical Technology

The US government will not give bluebird bio the opportunity to offer fertility support to patients covered by federal insurance programmes like Medicaid.

130
130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Welsh rugby great fronts UK atrial fibrillation campaign

pharmaphorum

Former Welsh rugby union captain Alum Wyn Jones is the face of a new awareness campaign launching in the UK today to draw attention to atrial fibrillation (AF), an irregular and potentially life-threatening heart rhythm abnormality.

115
115
article thumbnail

Telix raises $398m to advance kidney and brain cancer radiotherapies

Pharmaceutical Technology

Telix is eyeing an expansion of the diagnostic imaging indications for its assets and advancing pivotal trials as the radiopharma arena heats up.

Trials 130
article thumbnail

12 Questions with Irina Spirieva

pharmaphorum

Irina Spirieva, from Besins Healthcare, answers 12 intriguing questions about her journey in the healthcare industry. Learn more about her experiences and insights.

113
113
article thumbnail

FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosimilar

Pharmaceutical Technology

Samsung Bioepis has announced the approval of EPYSQLI BLA by the US Food and Drug Administration (FDA) as a biosimilar to Soliris.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Agilent builds its CDMO arm with $925m Biovectra buy

pharmaphorum

Agilent has boosted its contract development and manufacturing organisation (CDMO) capacity with a $925 million deal to buy Biovectra, a Canadian provider of fill-and-finish services and active pharmaceutical ingredients (APIs).It's a statement of intent from Agilent, whose primary business is lab instrumentation and equipment, suggesting that it intends to grow the outsourcing side of its business, which is currently focused on the production of oligonucleotide and peptide medicines.

article thumbnail

Agilent agrees to acquire BIOVECTRA for $925m

Pharmaceutical Technology

Agilent Technologies has announced a definitive agreement for the acquisition of Canadian CDMO BIOVECTRA in a deal worth $925m.

130
130
article thumbnail

MJFF awards $6m to Lario Therapeutics for Parkinson’s research

Pharma Times

The neurological disease is estimated to affect more than ten million people globally

Research 110
article thumbnail

Podcast #5: Doing Digital Deals in Life Sciences | Deal Structure, Terms, and Series Conclusions

Pharmaceutical Technology

Final podcast in Sterling's series, examining how a range of factors influence transaction structure and deal terms.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Pharma Pulse 7/23/24: The Data That Powers AI is Disappearing Fast, Stay Aware of Common High-Alert Medications & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

105
105
article thumbnail

Grünenthal gains Valinor Pharma and constipation drug Movantik

Pharmaceutical Technology

Grünenthal has announced the acquisition of Valinor Pharma and its opioid-induced constipation (OIC) therapy Movantik for $250m.

Drugs 130
article thumbnail

FDA Releases Draft Guidance on Essential Drug Delivery Outputs

FDA Law Blog

By Adrienne R. Lenz, Principal Medical Device Regulation Expert — For several years, FDA has requested that sponsors of drug or biologic led combination products identify essential performance requirements (EPRs) related to the device constituent in their applications. EPRs were usually requested in the context of design controls, although 21 C.F.R. § 820.30 does not use this term.

article thumbnail

GSK's Dovato matches rival Biktarvy with less weight gain

pharmaphorum

GSK has challenged Gilead's HIV behemoth Biktarvy, presenting data that its competing therapy Dovato is equally effective and associated with less weight gain.

105
105
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Agilent Purchases Biovectra for $925 Million

Pharmaceutical Commerce

The deal exponentially grows the CDMO’s biopharma capabilities.

104
104
article thumbnail

Breaking News: An Update on First and Third-Party Cookies – Privacy Implications on Paid Media

Intouch Solutions

Google has announced that it will not proceed with its initial plan – previously covered in this POV – to phase out third-party cookies on Chrome. Instead, Google will maintain the use of third-party cookies for those who do not disable them. This decision marks a shift from its previous strategy, which was aimed at enhancing user privacy while preserving advertising effectiveness.

article thumbnail

Ionis plans phase 3 for Biogen-rejected Angelman drug

pharmaphorum

Ionis plans phase 3 trial of its antisense therapy for Angelman syndrome, shortly after Biogen decided against exercising an option to license the drug

Drugs 104
article thumbnail

FDA Flags Potential ‘Overtreatment’ for NSCLC With AstraZeneca’s Imfinzi Ahead of Adcomm

BioSpace

AstraZeneca is proposing to use Imfinzi for resectable non-small cell lung cancer in the perioperative setting—both before and after surgical resection of the tumor. However, ahead of Thursday’s advisory committee meeting, FDA staffers have expressed concerns.

97
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

J&J files to expand label of depression drug Spravato

pharmaphorum

Johnson & Johnson has filed for FDA approval of its antidepressant nasal spray Spravato, hoping to make it the first standalone treatment for adults with treatment-resistant depression (TRD).Spravato (esketamine) is already approved in the US as an add-on to oral antidepressant therapy for TRD, as well as for depressive symptoms in adults with major depressive disorder (MDD) and suicidal thoughts or behaviours.

article thumbnail

Amylyx Rebuilds Momentum Following Relyvrio Market Withdrawal

BioSpace

While supportive of Amylyx’s acquisition of a GLP-1 drug, analysts say the company’s future hinges on key upcoming readouts from multiple products in its pipeline.

article thumbnail

Pluri’s CDMO arm takes on ALS and diabetes in cell therapy deal

BioPharma Reporter

The contract development and manufacturing organization (CDMO) arm of the Israeli company Pluri will deploy automated and 3D cell expansion technology to produce cell therapies developed by compatriot firm Kadimastem.

article thumbnail

Report: 2024 Job Market Trends, H2 Update

BioSpace

This report investigates anticipated job search activity and hiring outlook for the remainder of 2024.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.